Cargando…
Engineered soluble ACE2 receptor: Responding to change with change
SARS coronavirus 2 (SARS-CoV-2) invades the human body by binding to major receptors such as ACE2 via its S-spike protein, so the interaction of receptor-binding sites has been a hot topic in the development of coronavirus drugs. At present, the clinical progress in monoclonal antibody therapy that...
Autores principales: | Li, Guangyao, Qian, Kewen, Zhang, Shuyi, Fu, Wenyan, Zhao, Jian, Lei, Changhai, Hu, Shi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891289/ https://www.ncbi.nlm.nih.gov/pubmed/36741399 http://dx.doi.org/10.3389/fimmu.2022.1084331 |
Ejemplares similares
-
Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency
por: Fu, Wenyan, et al.
Publicado: (2023) -
CAR Macrophages for SARS-CoV-2 Immunotherapy
por: Fu, Wenyan, et al.
Publicado: (2021) -
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
por: Lei, Changhai, et al.
Publicado: (2020) -
The roles of small extracellular vesicles in cancer and immune regulation and translational potential in cancer therapy
por: Qian, Kewen, et al.
Publicado: (2022) -
Therapeutic antibodies under development for SARS‐CoV‐2
por: Ma, Zetong, et al.
Publicado: (2021)